Evidence map›Paper›PMID 40909956›Full record

ReviewFrontiers in oncology2025

Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.

Himisha Beltran, Jeremie Calais, Louise Emmett, Phillip H Kuo, Christopher J Logothetis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Real-world outcomes of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Variable cellular and radiobiological effects of [Journal of experimental & clinical cancer research : CR · 2026
    Article
  4. Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Himisha BeltranDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, United States.
Louise EmmettDepartment of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
Phillip H KuoDepartment of Radiology, City of Hope National Medical Center, Duarte, CA, United States.
Christopher J LogothetisDepartment of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [

Indexed as

[177Lu]Lu-PSMA-617biomarkersmetastatic castration-resistant prostate cancerprostate-specific membrane antigenradioligand therapy

Identifiers

PMID40909956
PMCPMC12405329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.